Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MAGE-A in triple-negative breast cancer: molecular biology, epigenetic targeting, and immunotherapy.

Epigenomics·2025

Same author

nNav1.5 mRNA Expression in Triple Negative and Non-Triple Negative Breast Cancer Patients Treated at Hospital Pakar Universiti Sains Malaysia.

Asian Pacific journal of cancer prevention : APJCP·2025

Same author

Next-generation sequencing in breast cancer: current clinical applications and future directions.

Annals of medicine·2025

Same author

Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention.

International reviews of immunology·2025

Same author

A Favourable Outcome in a Congenital Leukaemia Patient With Unique Cytogenetic Abnormalities.

Cureus·2024

Same author

Chromosome Translocation t(6; 14) With Different Phenotypes and Segregation Patterns: A Report of Two Cases.

Cureus·2024

Search research articles

Related Experiment Video

Updated: Jul 9, 2025

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

Association of ABCG2 Polymorphisms on Triple Negative Breast Cancer (TNBC) Susceptibility Risk.

Yeoh Hao Ing¹, Md Salzihan Md Salleh², Maya Mazuwin Yahya³

¹Human Genome Centre, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.

Asian Pacific Journal of Cancer Prevention : APJCP

|November 29, 2023

Summary

This summary is machine-generated.

The ABCG2 421 C>A gene polymorphism is linked to increased risk and specific aggressive subtypes of Triple Negative Breast Cancer (TNBC). This finding highlights the role of ABCG2 in TNBC development and progression.

Keywords:

ABCG2 polymorphisms Susceptibility risk TNBC

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Related Experiment Videos

Last Updated: Jul 9, 2025

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Area of Science:

Genetics and Genomics
Oncology
Molecular Biology

Background:

Triple Negative Breast Cancer (TNBC) is an aggressive subtype with limited targeted therapies.
The ATP-binding cassette super-family G member 2 (ABCG2) gene plays a role in drug resistance and cancer development.
Genetic variations, specifically polymorphisms, in ABCG2 may influence individual susceptibility to TNBC.

Purpose of the Study:

To investigate the association between common ABCG2 gene polymorphisms (34 G>A and 421 C>A) and susceptibility to TNBC.
To explore the correlation of these polymorphisms with clinicopathological variables in TNBC patients.

Main Methods:

Genotyping of ABCG2 34 G>A and 421 C>A polymorphisms using PCR-RFLP in 75 TNBC patients and 83 controls.
Statistical analysis of genotype data to determine associations with TNBC risk and clinicopathological features.

Main Results:

The ABCG2 421 C>A polymorphism (A allele and AA genotype) was significantly associated with an increased risk of developing advanced stage TNBC.
The AA genotype of ABCG2 421 C>A was linked to metaplastic and medullary carcinoma subtypes.
The 34G/421A haplotype of ABCG2 showed a significant association with advanced cancer staging and these specific TNBC subtypes.

Conclusions:

The ABCG2 421 C>A polymorphism is a potential genetic marker associated with increased susceptibility to TNBC.
This polymorphism is also linked to specific aggressive histological subtypes (metaplastic and medullary) and advanced staging in TNBC patients.